Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Data presented at the XXI World Congress of Neurology in Vienna suggest that DaTSCAN™ (Ioflupane I 123 Injection) SPECT imaging could add value to current diagnostic tools used by physicians to diagnose patients with dementia with Lewy bodies (DLB) by improving physician's ability to definitively diagnose the disorder and increase their confidence in so doing. DaTSCAN is GE Healthcare's radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging.
Data presented in two abstracts from a multicenter (21 centers in 6 European countries), randomized, open-label, comparative clinical trial evaluated the impact of DaTSCAN SPECT imaging on the clinical diagnosis of dementia and physician confidence of that diagnosis in patients with possible DLB who underwent DaTSCAN imaging (N=114) compared with those in the control group who did not (N=56). Specifically:
"The diagnosis of a patient with DLB can be challenging, particularly in patients with clinically uncertain DLB," said Igor Grachev, MD, Medical Director, GE Healthcare Life Sciences. "While the diagnosis often becomes clearer over time, particularly as signs and symptoms progress, in many cases true DLB can be missed. This study shows that DaTSCAN SPECT imaging, when used in combination with other core and suggestive features, has the ability to facilitate a more certain confident diagnosis."
DLB is one of the most common types of degenerative dementia, and is a common form of dementia in old age, accounting for nearly 15-20 percent of cases.[iii] The central feature of DLB is progressive cognitive decline, combined with three additional defining features: (1) pronounced "fluctuations" in alertness and attention, such as frequent drowsiness, lethargy, lengthy periods of time spent staring into space, or disorganized speech; (2) recurrent visual hallucinations, and (3) parkinsonian motor symptoms, such as rigidity and the loss of spontaneous movement.[iv]
DaTSCAN is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. DaTSCAN works by binding to dopamine transporters (DaT) in the brain. A specific marker for DaT, DaTSCAN produces images that provide visual evidence based on the density of dopamine transporters.
In July 2000, the European Commission granted a Marketing Authorization under the trade name DaTSCAN for use in detecting loss of functional dopaminergic neurons (nerve cells in the brain) in patients with clinically uncertain Parkinsonian syndrome (PS). In July 2006, the European indication was expanded to include differentiation of probable DLB from Alzheimer's Disease (AD). DaTSCAN is currently licensed and distributed in 34 countries, and has been in clinical use for ten years in more than 300,000 patients worldwide.
[i] Padovani A, Inglis F, Rainer M et al. Changes in Dementia Diagnostic Category and Diagnostic Confidence after DaTSCAN™ Imaging in Subjects with Possible Dementia with Lewy Bodies. Data presented at XXI World Congress of Neurology, September 26, 2013.
[ii] Walker Z, Thomas A, Tabet N, et al. Evolution of Symptoms and Signs Over 6-months in Subjects with Possible Dementia with Lewy Bodies Following DaTSCAN™ SPECT Imaging. Data presented at XXI World Congress of Neurology, September 24, 2013.
[iii] McKeith IG. Dementia with lewy bodies. British Journal of Psychiatry 2002. 180:144-147.
[iv] NINDS Dementia With Lewy Bodies Information Page. Accessed 9/17/2013 at: http://www.ninds.nih.gov/disorders/dementiawithlewybodies/dementiawithlewybodies.htm
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Medical Devices / Diagnostics category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Healthcare, GE. "New data show benefit of DaTSCAN™ (Ioflupane I 123 Injection) in the diagnosis of patients with clinically uncertain dementia with Lewy bodies." Medical News Today. MediLexicon, Intl., 1 Oct. 2013. Web.
11 Dec. 2013. <http://www.medicalnewstoday.com/releases/266790>
Healthcare, G. (2013, October 1). "New data show benefit of DaTSCAN™ (Ioflupane I 123 Injection) in the diagnosis of patients with clinically uncertain dementia with Lewy bodies." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/266790.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.